RxDoctor Payments DataLook up a doctor →

Shane Christensen, MD

Obstetrics · Salt Lake City, UTNPI 1861427189

Payments from drug & device makers

$24,657,368in general payments, 2019–2025

Across 3,655 payments — averaging $6746.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$14.3M
  • Modernatx, Inc.$7.7M
  • Sanofi Pasteur Inc.$1.1M
  • Merck$813K
  • AbbVie$355K
  • Seqirus USA Inc$217K
  • plus $128K from 44 others
$12,424in research payments, 2019–2025

Across 6 payments — averaging $2070.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$12K
  • Sanofi$500

What the payments were for

  • Travel & lodging$56610%
  • Food & beverage$5,18190%
  • Gifts$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few obstetrics providers in Utahto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$83,114
Medicare patients
128
Services billed
1,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$52,506
OzempicSemaglutide33$40,078
JardianceEmpagliflozin29$34,876
EliquisApixaban19$20,642
TrulicityDulaglutide17$17,964
MyrbetriqMirabegron22$12,340
Atorvastatin Calcium412$4,663
Omeprazole142$3,062
Testosterone21$2,937
Gabapentin79$1,950
Zolpidem Tartrate134$1,630
Rosuvastatin Calcium113$1,391
Metformin Hcl96$1,277
Trazodone Hcl116$1,252
Bupropion XlBupropion Hcl43$1,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$498$71,58470 claims
Novo NordiskOzempic$63$40,07833 claims
Boehringer IngelheimJardiance$366$34,87629 claims
PfizerEliquis$14,332,147$20,64219 claims
Astellas Pharma US IncMyrbetriq$74$12,34022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obstetrics providers in Utahon file to place this against a meaningful peer group, so we don't.

Other obstetrics in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →